Trial Profile
The impact of additive EPA or ezetimibe to statin therapy on the stabilization of vulnerable plaque; Assessment by OCT
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jun 2014
Price :
$35
*
At a glance
- Drugs Eicosapentaenoic acid (Primary) ; Ezetimibe (Primary) ; HMG-CoA reductase inhibitors
- Indications Hyperlipoproteinaemia; Ischaemic heart disorders
- Focus Therapeutic Use
- 25 Jun 2014 New trial record